Corbus Pharmaceuticals Holdings, Inc. Stock
Equities
CRBP
US21833P3010
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.04 USD | +3.93% | -1.85% | +513.25% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 389M |
---|---|---|---|---|---|
Net income 2024 * | -53M | Net income 2025 * | -65M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.12
x | P/E ratio 2025 * |
-7.23
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.31% |
Latest transcript on Corbus Pharmaceuticals Holdings, Inc.
1 day | +3.93% | ||
1 week | -1.85% | ||
1 month | -5.61% | ||
3 months | +39.83% | ||
6 months | +579.63% | ||
Current year | +513.25% |
Managers | Title | Age | Since |
---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Sean Moran
DFI | Director of Finance/CFO | 66 | 14-04-10 |
Chief Tech/Sci/R&D Officer | 50 | Feb. 27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Holmer
CHM | Chairman | 74 | 13-12-31 |
Avery Catlin
BRD | Director/Board Member | 75 | 14-07-31 |
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 37.04 | +3.93% | 197,603 |
24-04-29 | 35.64 | +4.06% | 92,849 |
24-04-26 | 34.25 | +2.24% | 96,876 |
24-04-25 | 33.5 | -5.74% | 142,333 |
24-04-24 | 35.54 | -5.83% | 221,002 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+513.25% | 389M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.21% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- CRBP Stock